In vitro cytotoxic activity of phytosynthesized silver nanoparticles using Clematis vitalba L. (Ranunculaceae) aqueous decoction

In this study, we report a bottom-up approach for silver nanoparticles (AgNPs) synthesis using aqueous decoction of aerial parts of Clematis vitalba L. The phytosynthesized AgNPs were characterized by X-ray diffraction (XRD), UV-vis spectroscopy, Fourier Transform-Infrared Spectroscopy (FTIR), Scanning Electron Microscopy coupled with Energy Dispersive X-ray Spectroscopy (SEM-EDS) and Bright Field Scanning Transmission Electron Microscopy (BFSTEM). The cytogenotoxicity and phytotoxicity assays of AgNPs were assessed by using Allium test, Evans blue and 2, 3, 5-triphenyl tetrazolium chloride (TTC) staining, root and stem growth potential, and biomass evaluation. The results revealed that AgNPs were in the size range of 1-15 nm and spherical shape. The biosynthesized AgNPs augment the mitodepressive effect, disruption of cellular metabolism, impairment of root and stem growth, and biomass reduction induced by C. vitalba aqueous extracts. These results outline the toxicological profile of the C. vitalba extracts, as well as of the phytogenerated AgNPs and provides scientific perspectives on the use of C. vitalba extracts as reducing and stabilizing agent for the phytosynthesis of metallic nanoparticles

Current Situation and Future Perspectives of the Romanian Renewable Energy

In 2015, Romania was the first country in Europe that achieved EU targets regarding the share of renewables in the generation mix, far ahead of the 2020 deadline. Starting with the energy structure in Romania, the paper: (1) analyses the evolution of the main indicators in the renewable energy sector, (2) discloses the perspectives of renewable energy in Romania synthesizing the main trends of development in the field, and (3) analyses the challenges facing with the development of renewable energy in Romania. Based on analyzing the exploratory data, the paper makes a preliminary prediction of the development of the sector for future decades and proposes targeted countermeasures and suggestions. Romania still has unexploited potential concerning renewable energy sources. Since Romania registered continuous economic growth, the demand for electricity is steadily growing, and this trend is expected to continue. Additionally, Romania could introduce a support mechanism for developing the potential of unexploited existing resources. The results of the present study may be useful for further research regarding public policies for the development of renewable energy. Furthermore, it can represent a useful analysis in order to identify future trends of renewable energy in Romania

Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review

In the 2016 revision of the World Health Organization classification the term therapy-related myeloid neoplasia (t-MN) defines a subgroup of acute myeloid leukemia (AML) comprising patients who develop myelodysplastic syndrome (MDS-t) or acute myeloid leukemia (AML-t) after treatment with cytotoxic and/or radiation therapy for various malignancies or autoimmune disorders. We report the case of a 36 year old patient with t-MN (t-MDS) after achieving complete remission (CR) of a PML-RARA positive acute promyelocytic leukemia (APL) at 32 months after diagnosis. Initially classified as low risk APL and treated according to the AIDA protocol - induction and 3 consolidation cycles - the patient achieved a complete molecular response in September 2013 and started maintenance therapy. On follow-up PML-RARA transcript remained negative. In January 2016 leukopenia and thrombocytopenia developed and a peripheral blood smear revealed hypogranular and agranular neutrophils. Immunophenotyping in the bone marrow aspirate identified undifferentiated blast cells that did not express cytoplasmic myeloperoxidase. The cytogenetic study showed normal karyotype. The molecular biology tests not identified PMLRARA transcript. A diagnosis of t-MDS (AREB-2 - WHO 2008) was established. Treatment of AML was started with 2 “3+7” regimens and 1 MEC cycle. Two months from diagnosis, while in CR, an allogeneic HSCT from an unrelated HLA compatible donor was performed after myeloablative regimen. An unfavorable clinical evolution was followed by death on day 9 after transplantation. The occurrence of t-MNs during CR of APL represents a particular problem in terms of follow-up and differential diagnosis of relapse and constitutes a dramatic complication for a disease with a favorable prognosis

Quality-of-Life Assessment after Head and Neck Oncological Surgery for Advanced-Stage Tumours

Squamous cell carcinoma of the head and neck (HNSCC) is a common malignancy often diagnosed in the advanced stage with a complex negative influence on the patient’s quality of life (QoL). Given its multi-modal treatment, the first step is to adequately balance the needs of the patient, and the second step includes the consultations, interventions, and care provided by the medical team, with the purpose of improving the overall management of the HNSCC. Current attempts to develop and validate quality-of-life instruments specific to cancers of the head and neck have been reported, and certain questionnaires are now available. We performed a retrospective study in a tertiary centre, involving 89 patients who survived 3 years after HNSCC surgery. A patient-related outcome measurement was made using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-H&N35 instruments to assess QoL at admission and 3 years after treatment. The 3-year survivors reported an overall improvement in QoL compared with those in the pre-treatment period. The unique details of head and neck cancer treatments outline the importance of considering the characteristics of the patient population in quality-of-life research and also identify how quality-of-life data can contribute to the care provided by the multi-disciplinary team involved in a patient’s follow-up